Clinical trial · Observational
MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer
A Prospective, Multicenter, Prospective, Non-intervention, Controlled Trial of MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer in Realistic Medical Practice
NCT03400657CI-TRIAL-00031229unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, multicenter, non-interventional, controlled clinical study. Evaluate MDT performance and benefit analysis in patients with advanced gastric or colorectal cancer after MDT discussion under real medical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multi-disciplinary Treatment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multi-disciplinary Treatment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- fully implemented to the MDT decision
- description
- group of patients fully implemented to the MDT decision
- interventionNames
- Procedure: Multi-disciplinary Treatment
- label
- not completly implemented to the MDT-decision
- description
- group of patients not completly implemented to the MDT decision
- interventionNames
- Procedure: Multi-disciplinary Treatment
- label
- not implemented to the MDT decision
- description
- group of patients not implemented to the MDT decision
- interventionNames
- Procedure: Multi-disciplinary Treatment
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Histopathological diagnosis of recurrent / metastatic gastric or colorectal cancer. 2. Participate in formal MDT discussions at the Research Center. 3. MDT decision-making at least two subjects involved in treatment. 4. Patient informed consent and signed written consent. Exclusion Criteria: 1. Early or locally advanced gastric cancer or colorectal cancer. 2. Accept informal MDT discussions. 3. MDT decisions recommend only a single subject for treatment of patients. 4. MDT decisions recommend only palliative patients.
References
Publications (0)
Data not yet available
No reference posted for this study.